Protagenic Therapeutics, Inc. (PTIX)
NASDAQ: PTIX · Real-Time Price · USD
0.409
+0.005 (1.14%)
Jan 22, 2025, 1:40 PM EST - Market open
Protagenic Therapeutics Employees
As of December 31, 2023, Protagenic Therapeutics had 3 total employees, including 1 full-time and 2 part-time employees. The number of employees increased by 2 or 200.00% compared to the previous year.
Employees
3
Change
2
Growth
200.00%
Revenue / Employee
n/a
Profits / Employee
-$1,882,595
Market Cap
2.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 2 | 200.00% |
| Dec 31, 2015 | 1 | 0 | - |
| Dec 31, 2014 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
PTIX News
- 2 months ago - Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - Accesswire
- 3 months ago - Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million - Accesswire
- 9 months ago - Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial - Accesswire
- 10 months ago - Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit - Accesswire
- 10 months ago - Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript - Seeking Alpha
- 10 months ago - Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results - Accesswire
- 10 months ago - Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders - Accesswire
- 10 months ago - Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call - Accesswire